Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 27, 2024
Emerging Company Profile
Valora: Blocking cancer’s immune evasion via glycan targeting
San Diego-based company’s antibody-lectin chimeras act as molecular decoys to disrupt cellular interactions
BioCentury | Dec 22, 2023
Distillery Therapeutics
Bispecific SIGLEC7xFSHR NK cell engager for ovarian cancer
BioCentury | Jul 2, 2021
Distillery Therapeutics
Targeting SIGLEC7, SIGLEC9 in solid tumors
DISEASE CATEGORY: Cancer
INDICATION: Colorectal cancer; melanoma Targeting the myeloid receptors SIGLEC7 and SIGLEC9 could treat colorectal cancer and melanoma. In a mouse model of melanoma
INDICATION: Colorectal cancer; melanoma Targeting the myeloid receptors SIGLEC7 and SIGLEC9 could treat colorectal cancer and melanoma. In a mouse model of melanoma
BioCentury | Jan 4, 2020
Targets & Mechanisms
SIGLECs go from homing beacons to next-generation checkpoints
Why SIGLECs are rising in the landscape of next-generation checkpoint targets
BioCentury | Dec 8, 2017
Targets & Mechanisms
Epiphenomena at ASH
Epigenetics and cell therapies are preclinical hotspots at ASH 2017
Items per page:
1 - 7 of 7